Synthego Gets PTAB To Ax 2 Agilent CRISPR Patents
The Patent Trial and Appeal Board found Wednesday that two Agilent Technologies Inc. patents on the gene-editing tool CRISPR were invalid, the latest dustup in a legal fight brought by Synthego...To view the full article, register now.
Already a subscriber? Click here to view full article